BoB@JPM: Ron Cooper, enGene

BoB@JPM: Ron Cooper, enGene

Author: Ben Comer January 26, 2026 Duration: 55:57

We love to hear from our listeners. Send us a message.

On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing early in CMC, and what to expect in 2026.  

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/



Navigating the complex journey from a promising scientific idea to a commercially viable therapy involves far more than lab work. Business Of Biotech, hosted by Ben Comer, exists in that crucial space where scientific ambition meets real-world execution. This podcast speaks directly to the founders, executives, and visionaries steering emerging biopharma companies, offering a grounded conversation about the non-scientific hurdles that define success. You'll hear detailed discussions on the organizational, financial, and operational realities of the industry-from securing funding and building a team to managing clinical trials, manufacturing, and regulatory pathways. Each episode leans on the hard-earned wisdom of accomplished guests who share commentary and practical best practices. The focus is consistently on the multifaceted challenges leaders face while trying to bring a company from its earliest stages to impact in the clinic and the market. For anyone involved in building a life sciences company, this podcast provides an essential, candid look at the entire ecosystem, making the daunting path of biotech entrepreneurship feel a bit more navigable and a lot less lonely.
Author: Language: English Episodes: 100

Business Of Biotech
Podcast Episodes
True DEI Value in Biopharma with Arcellx's Rami Elghandour [not-audio_url] [/not-audio_url]

Duration: 1:04:08
We love to hear from our listeners. Send us a message. The cell therapy company Arcellx has, by any and every measure, been outperforming its peers. Its stock has rallied on the back of the strong performance of its mult…
Mission-Driven Dementia Funding with DDF's Jonathan Behr [not-audio_url] [/not-audio_url]

Duration: 55:46
We love to hear from our listeners. Send us a message. If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonat…
ADCs Ignited with Daiichi Sankyo Inc.'s Ken Keller [not-audio_url] [/not-audio_url]

Duration: 1:04:06
We love to hear from our listeners. Send us a message. Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. But then, just a few ye…
Accelerating ADCs with Mythic Therapeutics' Brian Fiske, Ph.D. [not-audio_url] [/not-audio_url]

Duration: 56:38
We love to hear from our listeners. Send us a message. Mythic Therapeutics Chief Scientific Officer and co-founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia…
The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's Thomas Leitch [not-audio_url] [/not-audio_url]

Duration: 57:35
We love to hear from our listeners. Send us a message. This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company a CDMO. He's not wrong. While some…
A New Prescription For PBMs with Allan Shaw [not-audio_url] [/not-audio_url]

Duration: 40:13
We love to hear from our listeners. Send us a message. Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (…
New Apps For AI in mRNA With Anima Biotech's Yochi Slonim [not-audio_url] [/not-audio_url]

Duration: 59:10
We love to hear from our listeners. Send us a message. From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global tech hubs around the gl…
Physician + Biotech Builder with Tome Biosciences' Rahul Kakkar, M.D. [not-audio_url] [/not-audio_url]

Duration: 1:01:30
We love to hear from our listeners. Send us a message. Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed b…

«1...678910